Myopic Choroidal Neovascularization: Diagnosis and Treatment Update

Mariana R. Thorell, Raquel Goldhardt

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: To review the diagnosis and treatment of myopic choroidal neovascularization. Imaging tests currently available and the advantages of each modality for detecting choroidal neovascularization signs are discussed. The management options and the outcomes of different treatment options are also reviewed. Recent Findings: Anti-vascular endothelial growth factor has become the preferable choice of treatment in myopic choroidal neovascularization cases with improved results. The benefits of a single injection followed by PRN dosing were supported by randomized clinical trials. Summary: Choroidal neovascularization is a common vision threatening complication in patients with pathologic myopia. Most of the patients with this condition are younger than 50 years, and the major concern is to have vision preserved later in life. The investigation of myopic choroidal neovascularization imposes additional tests to be performed in most cases. Anti-vascular endothelial growth therapy has demonstrated superior efficacy over other treatment modalities. However, further studies are required for investigation of the risk factors for recurrences and the long-term treatment strategies.

Original languageEnglish (US)
Pages (from-to)59-65
Number of pages7
JournalCurrent Ophthalmology Reports
Issue number1
StatePublished - Mar 15 2019


  • Choroidal neovascularization
  • Degenerative myopia
  • Optical coherence tomography
  • Pathological myopia
  • Vascular endothelial growth factors

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Myopic Choroidal Neovascularization: Diagnosis and Treatment Update'. Together they form a unique fingerprint.

Cite this